Table 1.
Demographic, clinical, laboratory characteristics and auxiliary medication in 101 ulcerative colitis cases before initial administration of corticosteroid n (%)
| Prolonged response | Dependence | Refractoriness | Total | |
| Cases | 42 | 50 | 9 | 101 |
| Female | 24 (57.1) | 22 (44.0) | 2 (22.8) | 48 (47.5) |
| Age (≥ 30 yr) | 39 (92.8) | 41 (82.0) | 6 (66.7) | 85 (84.2) |
| Disease duration (≥ 5 yr) | 12 (29.3) | 15 (31.9) | 2 (22.2) | 29 (33.3) |
| Relapse frequency (> 3/yr) | 2 (5.9) | 4 (9.3) | 0 | 6 (7.0) |
| Previous colectomy | 4 (9.5) | 3 (6.0) | 1 (11.1) | 8 (7.9) |
| UC location | ||||
| Proctitis | 7 (17.5) | 6 (12.2) | 2 (22.2) | 15 (15.3) |
| Left-side colitis | 5 (12.5) | 9 (18.4) | 1 (11.1) | 15 (15.3) |
| Extensive colitis | 28 (70.0) | 34 (69.4) | 6 (66.7) | 68 (69.4) |
| Sutherland score | ||||
| Mild (3-5) | 2 (4.8) | 2 (4.0) | 1 (11.1) | 5 (5.0) |
| Moderate (6-10) | 21 (50.0) | 25 (50.0) | 2 (22.2) | 48 (47.5) |
| Severe (11-12) | 19 (45.2) | 23 (46.0) | 6 (66.7) | 48 (47.5) |
| Heart rate (≥ 90/min) | 8 (19.5) | 18 (36.0) | 5 (55.6) | 31 (31.0) |
| Diarrhea (≤ 6/d) | 14 (33.3) | 25 (50.0) | 4 (44.4) | 43 (42.6) |
| Bloody stool | 34 (80.1) | 44 (88.0) | 8 (88.9) | 86 (85.1) |
| Mucus | 34 (81.0) | 39 (78.0) | 6 (66.7) | 79 (78.2) |
| Tenesmus | 25 (59.5) | 16 (32.0) | 4 (44.4) | 45 (44.6) |
| Abdominal pain | 34 (81.0) | 47 (94.0) | 9 (100.0) | 90 (89.1) |
| Abdominal distention | 6 (14.3) | 8 (16.0) | 4 (44.4) | 18 (17.8) |
| Weight loss | 17 (40.5) | 18 (36.0) | 7 (77.8) | 42 (41.6) |
| Fever | 13 (31.0) | 13 (26.0) | 5 (55.6) | 31 (30.7) |
| Extra-intestinal manifestation | 6 (14.3) | 7 (14.0) | 2 (22.2) | 15 (14.9) |
| Hemoglobin (< 12.0 mg/dL) | 32 (76.2) | 31 (62.0) | 9 (100.0) | 72 (71.3) |
| Leukocyte (4-10 × 109/L) | 21 (50.0) | 29 (58.0) | 9 (100.0) | 59 (58.4) |
| Neutrophil (50%-70%) | 20 (47.6) | 28 (56.0) | 6 (66.7) | 54 (53.5) |
| Platelet (> 300 × 1012/L) | 26 (61.9) | 26 (52.0) | 4 (44.4) | 56 (55.4) |
| Albumin (< 3.5 mg/dL) | 27 (64.3) | 27 (54.0) | 5 (55.6) | 59 (58.4) |
| K+ (< 3.5 mmol/L) | 16 (15.8) | 16 (32.0) | 3 (33.3) | 35 (34.7) |
| ESR (> 15 mm/h) | 27 (64.3) | 27 (54.0) | 7 (77.8) | 61 (60.4) |
| Auxiliary medication | ||||
| None | 2 (4.8) | 7 (14.0) | 1 (11.1) | 10 (9.9) |
| Only SASP or 5-ASA (A) | 32 (76.2) | 29 (58.0) | 5 (55.6) | 66 (65.3) |
| Only immunosuppressant (B) | 1 (2.4) | 4 (8.0) | 1 (11.1) | 6 (5.9) |
| Only infliximab (C) | 0 | 0 | 0 | 0 |
| A + B | 6 (14.3) | 9 (18.0) | 2 (22.2) | 17 (16.8) |
| A + C | 1 (2.4) | 1 (2.0) | 0 | 2 (2.0) |
The demographic, clinical and laboratory characteristic were displayed respectively according to the cohorts of different corticosteroid response. The auxiliary medication after the start of corticosteroid treatment was also displayed. UC: Ulcerative colitis; ESR: Erythrocyte sediment rate; 5-ASA: 5-aminosalicylates; SASP: Sulfasalazine.